Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P07101
UPID:
TY3H_HUMAN
Alternative names:
Tyrosine 3-hydroxylase
Alternative UPACC:
P07101; B7ZL70; B7ZL73; Q0PWM2; Q0PWM3; Q15585; Q15588; Q15589; Q2M3B4
Background:
Tyrosine 3-monooxygenase, also known as Tyrosine 3-hydroxylase, plays a pivotal role in the biosynthesis of catecholamines, including dopamine, noradrenaline, and adrenaline. It catalyzes the conversion of L-tyrosine to L-DOPA, the rate-limiting step in catecholamine synthesis, utilizing tetrahydrobiopterin and molecular oxygen. This enzyme's activity extends beyond tyrosine, as it can also hydroxylate phenylalanine and tryptophan with lower specificity.
Therapeutic significance:
The enzyme's deficiency is linked to Segawa syndrome autosomal recessive, a treatable dystonia due to its favorable response to L-DOPA. Understanding the role of Tyrosine 3-monooxygenase in this condition highlights its therapeutic significance, offering insights into potential treatments for related neurological disorders.